Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

• Váldodahkkit: Yanlin Zhu (Dahkki), Shuangshuang Xu (Dahkki), Yi Lu (Dahkki), Yijuan Wei (Dahkki), Benqiang Yao (Dahkki), Fusheng Guo (Dahkki), Xing Zheng (Dahkki), Yumeng Wang (Dahkki), Ying He (Dahkki), Lihua Jin (Dahkki), Yong Li (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...